---
input_text: 'The role of vagus nerve stimulation in genetic etiologies of drug-resistant
  epilepsy: a meta-analysis. OBJECTIVE: Drug-resistant epilepsy (DRE) affects many
  children. Vagus nerve stimulation (VNS) may improve seizure control; however, its
  role in children with genetic etiologies of epilepsy is not well described. The
  authors systematically reviewed the literature to examine the effectiveness of VNS
  in this cohort. METHODS: In January 2021, the authors performed a systematic review
  of the PubMed/MEDLINE, SCOPUS/Embase, Cochrane, and Web of Science databases to
  investigate the impact of VNS on seizure outcomes in children with genetic etiologies
  of epilepsy. Primary outcomes included seizure freedom rate, >= 90% seizure reduction
  rate, and >= 50% seizure reduction rate. Secondary outcomes were seizure severity
  and quality of life (QOL), including cognitive, functional, and behavioral outcomes.
  A random-effects meta-analysis was performed. RESULTS: The authors identified 125
  articles, of which 47 with 216 nonduplicate patients were analyzed. Common diagnoses
  were Dravet syndrome (DS) (92/216 patients [42.6%]) and tuberous sclerosis complex
  (TSC) (63/216 [29.2%]). Seizure freedom was not reported in any patient with DS;
  the pooled proportion (95% CI) of patients with >= 50% seizure reduction was 41%
  (21%-58%). Secondary cognitive outcomes of VNS were variable in DS patients, but
  these patients demonstrated benefits in seizure duration and status epilepticus.
  In TSC patients, the pooled (95% CI) seizure freedom rate was 40% (12%-71%), >=
  90% seizure reduction rate was 31% (8%-56%), and >= 50% reduction rate was 68% (48%-91%).
  Regarding the secondary outcomes of VNS in TSC patients, several studies reported
  decreased seizure severity and improved QOL outcomes. There was limited evidence
  regarding the use of VNS to treat patients with other genetic etiologies of epilepsy,
  such as mitochondrial disease, Rett syndrome, Doose syndrome, Landau-Kleffner syndrome,
  Aicardi syndrome, Angelman syndrome, ring chromosome 20 syndrome, and lissencephaly;
  variable responses were reported in a limited number of cases. CONCLUSIONS: The
  authors conducted a systematic review of VNS outcomes in children with genetic etiologies
  of DRE. Among the most studied conditions, patients with TSC had substantial seizure
  reduction and improvements in QOL, whereas those with DS had less robust seizure
  reduction. Increased testing, diagnosis, and long-term follow-up studies are necessary
  to better characterize VNS response in these children.'
raw_completion_output: |-
  primary_disease: Drug-resistant epilepsy (DRE)

  medical_actions: Vagus nerve stimulation (VNS); Systematic review; Meta-analysis; Seizure control; Seizure freedom; Seizure reduction; Review of seizure severity; Quality of life assessment

  symptoms: Seizure; Seizure severity; Status epilepticus

  chemicals: 

  action_annotation_relationships: Vagus nerve stimulation (VNS) TREATS seizure IN Drug-resistant epilepsy (DRE); Vagus nerve stimulation (VNS) TREATS seizure severity IN Drug-resistant epilepsy (DRE); Vagus nerve stimulation (VNS) TREATS status epilepticus IN Drug-resistant epilepsy (DRE)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Vagus nerve stimulation (VNS) TREATS status epilepticus IN Drug-resistant epilepsy (DRE)

  ===

extracted_object:
  primary_disease: Drug-resistant epilepsy (DRE)
  medical_actions:
    - MAXO:0000942
    - Systematic review
    - Meta-analysis
    - Seizure control
    - Seizure freedom
    - Seizure reduction
    - Review of seizure severity
    - Quality of life assessment
  symptoms:
    - HP:0001250
    - Seizure severity
    - HP:0002133
  action_annotation_relationships:
    - subject: <Vagus nerve stimulation>
      predicate: <TREATS>
      object: <seizure>
      qualifier: <Drug-resistant epilepsy>
      subject_qualifier: <null>
      object_qualifier: <null>
      subject_extension: <Vagus nerve stimulation>
      object_extension: <null>
    - subject: MAXO:0000942
      predicate: TREATS
      object: seizure severity
      qualifier: Drug-resistant epilepsy (DRE)
    - subject: MAXO:0000942
      predicate: TREATS
      object: HP:0002133
      qualifier: Drug-resistant epilepsy
      subject_extension: Vagus nerve stimulation
named_entities:
  - id: MONDO:0100135
    label: Dravet syndrome
  - id: MAXO:0001187
    label: hysteroscopy
  - id: CHEBI:44915
    label: propofol
  - id: CHEBI:119915
    label: fentanyl
  - id: CHEBI:9130
    label: sevoflurane
  - id: HP:0001250
    label: seizures
  - id: CHEBI:6443
    label: Mirena
  - id: MONDO:0002602
    label: Central nervous system diseases
  - id: HP:0002011
    label: central nervous system diseases
  - id: MONDO:0005027
    label: Epilepsy
  - id: HP:0002014
    label: Diarrhea
  - id: HP:0000988
    label: Rash
  - id: CHEBI:228488
    label: Stiripentol
  - id: CHEBI:60654
    label: Valproate
  - id: CHEBI:69478
    label: Cannabidiol
  - id: CHEBI:80634
    label: 2-propyl-4-pentenoic acid (4-ene-VPA)
  - id: HP:0002373
    label: Febrile seizures
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:31413
    label: clobazam (CLB)
  - id: HP:0010819
    label: drop seizures
  - id: HP:0002329
    label: somnolence
  - id: HP:0004396
    label: decreased appetite
  - id: CHEBI:9925
    label: sodium valproate
  - id: MONDO:0016532
    label: Lennox-Gastaut syndrome
  - id: HP:0000729
    label: Autistic behaviors
  - id: HP:0033258
    label: Sudden unexpected death in epilepsy
  - id: MAXO:0001001
    label: Gene therapy
  - id: MONDO:0002125
    label: Status epilepticus
  - id: HP:0032656
    label: Febrile status epilepticus
  - id: MAXO:0001017
    label: vaccination
  - id: HP:0002069
    label: Generalized tonic-clonic seizure
  - id: CHEBI:3359
    label: CBDA
  - id: CHEBI:167557
    label: CBCA
  - id: CHEBI:66964
    label: Delta9-tetrahydrocannabinol (THC)
  - id: CHEBI:39867
    label: Valproic acid
  - id: CHEBI:5000
    label: Fenfluramine
  - id: HP:0033349
    label: recurrent seizures
  - id: MAXO:0000058
    label: Drug treatment
  - id: HP:0020219
    label: motor seizures
  - id: CHEBI:76720
    label: Antisense oligonucleotides
  - id: MAXO:0001593
    label: ASO therapy
  - id: HP:0012378
    label: Fatigue
  - id: HP:0001945
    label: Pyrexia
  - id: HP:0001654
    label: valvular heart disease
  - id: HP:0002092
    label: pulmonary arterial hypertension
  - id: HP:0002133
    label: Status epilepticus
  - id: CHEBI:17115
    label: vaccine(s)
  - id: MONDO:0100062
    label: Developmental and/or epileptic encephalopathies (DEE)
  - id: HP:0001260
    label: dysarthria
  - id: HP:0001254
    label: lethargy
  - id: HP:0002315
    label: headache
  - id: CHEBI:233158
    label: soticlestat
  - id: CHEBI:34310
    label: 24S-hydroxycholesterol (24HC)
  - id: CHEBI:9586
    label: Tiagabine
  - id: CHEBI:6437
    label: Levetiracetam
  - id: HP:0000708
    label: behavioral problems
  - id: CHEBI:16113
    label: Cholesterol
  - id: MAXO:0001394
    label: Oral administration
  - id: CHEBI:173124
    label: 2-linoleoyl glycerol (2-LG)
  - id: CHEBI:52392
    label: 2-AG
  - id: CHEBI:2700
    label: anandamide
  - id: CHEBI:52640
    label: N-acylethanolamines
  - id: CHEBI:35623
    label: Anticonvulsants
  - id: MAXO:0000942
    label: Vagus nerve stimulation (VNS)
  - id: HP:0002360
    label: Sleep disturbance
  - id: HP:0001249
    label: Intellectual disability
  - id: HP:0001251
    label: ataxia
  - id: CHEBI:42638
    label: fenfluramine (FFA)
  - id: HP:0032794
    label: Myoclonic seizures
  - id: CHEBI:190616
    label: N-desmethylclobazam
  - id: MONDO:0013801
    label: SCN8A encephalopathy
  - id: HP:0001263
    label: Developmental delay
  - id: HP:0100543
    label: Cognitive impairment
  - id: CHEBI:35493
    label: antipyretics
  - id: MAXO:0000932
    label: Electroencephalography (EEG)
  - id: HP:0002353
    label: EEG abnormalities
  - id: CHEBI:73601
    label: <Ketogenic diet (KD)>
  - id: CHEBI:49575
    label: diazepam
  - id: CHEBI:6931
    label: midazolam
  - id: CHEBI:3756
    label: clonazepam
  - id: CHEBI:22720
    label: Benzodiazepines
  - id: MONDO:0010083
    label: Succinic semialdehyde dehydrogenase deficiency
  - id: HP:0000739
    label: Anxiety
  - id: CHEBI:10127
    label: Zonisamide
  - id: CHEBI:87016
    label: Eslicarbazepine acetate
  - id: CHEBI:135939
    label: Lacosamide
  - id: MONDO:0700092
    label: Neurodevelopmental disorders (NDDs)
  - id: CHEBI:63631
    label: Topiramate
  - id: CHEBI:15858
    label: Bromides
  - id: MAXO:0000127
    label: Genetic testing
  - id: MONDO:0008297
    label: Vaccine proximate seizures (VPS)
